This study developed a mitochondria-related genes prognostic model using machine learning algorithm. The prognostic model exhibits promising prognostic values and has the ability to provide evidence for the selection of appropriate targeted therapy and immunotherapy.

Given the big changes in the entities included in each subtype under the 2021 CNS tumor classification, the effect of TERTp mutation on prognosis and the relationship between TERTp mutation and other molecular alterations in different subgroups should be reevaluated. In this research, we investigated the distribution, prognostic value, and molecular correlation of TERTp mutation under this latest classification. Survival analysis showed that TERTp mutation was a predictor of better prognosis in IDH-mutant grade 2 gliomas, while poor OS was associated with all Grade 4 gliomas and all IDH-wildtype histology grade 2 or 3 gliomas. The correlation between TERTp mutation and other molecular alterations was multiform in different subgroups, which needs to be investigated further.

We report analyses from post-marketing surveillance of avelumab + axitinib treatment in patients with advanced renal cell carcinoma in Japan in age subgroups: ≤64 years (n = 100), 65–74 years (n = 130), and ≥75 years (n = 98). Overall, safety and effectiveness were similar across age subgroups, suggesting that age alone is not a relevant consideration for avelumab + axitinib treatment. The favorable benefit–risk profile was generally consistent with that observed in previous clinical studies, further supporting the use of avelumab + axitinib treatment in this disease setting.

Combined analysis of the content from tissue-derived EVs and serum-derived EVs can better identify early biomarkers of pancreatic ductal adenocarcinoma (PDAC). Our study identifies two specific miRNAs, miR142-3p and miR148a-3p, as diagnostic serum biomarkers for PDAC. Tissue-derived EVs are found in the interstitial space and are important for intercellular communication. These results indicate that the combination of miR142-3p, miR148a-3p, and CA199 was more accurate than CA199 alone in predicting clinical outcomes. Combined analysis of tissue-derived EVs with serum-derived EVs could be more accurate, as tissue-derived EVs could be more specific than serum-derived EVs.

We report data from prospective, noncomparative, multicenter, observational post-marketing surveillance in patients with curatively unresectable or metastatic renal cell carcinoma who received avelumab + axitinib in Japan between December 2019 and May 2021 (N = 328). Adverse drug reactions of safety specifications of any grade occurred in 52.7% of patients, disease control rate was 75.6%, and the 12-month OS rate was 83.7%. Our results confirmed the safety, tolerability, and effectiveness of avelumab + axitinib in patients with renal cell carcinoma in clinical practice in Japan, with a benefit–risk profile comparable to that observed in clinical trials.

This study represents the first comprehensive integration of whole-exome and RNA sequencing to compare the molecular profiles of borderline ovarian tumors (BOTs) with high-grade serous carcinoma, endometrioid carcinoma (EC), and clear-cell carcinoma. Our findings reveal notable genomic and transcriptomic similarities between BOTs and ECs, suggesting shared oncogenic pathways. These insights could reshape the molecular classification of ovarian tumors and influence future therapeutic strategies.